Login to Your Account



RIBO REVS UP LETROZOLE

Ribociclib ups survival in postmenopausal Asian women with advanced breast cancer

By John Fox
Staff Writer

Tuesday, December 27, 2016

HONG KONG – The cyclin-dependent kinase (CDK) 4/6 pathway inhibitor, ribociclib (LEE011, Novartis AG), in combination with Femara (letrozole, Novartis AG), significantly improved progression-free survival (PFS) in postmenopausal Asian women with advanced breast cancer, in a subanalysis of the MONALEESA-2 trial.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription